Protective effects of SGLT2 inhibitor luseogliflozin on pancreatic β-cells in obese type 2 diabetic db/db mice

Biochemical and Biophysical Research Communications

Volumn 470, Issue 3, 2016, Pages 772-782

  Okauchi, Seizo ^a   Shimoda, Masashi ^a   Obata, Atsushi ^a   Kimura, Tomohiko ^a   Hirukawa, Hidenori ^a   Kohara, Kenji ^a   Mune, Tomoatsu ^a   Kaku, Kohei ^a   Kaneto, Hideaki ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Pancreatic cells; SGLT2 inhibitor; cell mass and function

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 3; FIBRONECTIN; GLUCOSE; GLUCOSE TRANSPORTER 2; INSULIN; LUSEOGLIFLOZIN; TRANSCRIPTION FACTOR MAFA; TRANSCRIPTION FACTOR PDX 1; TRANSFORMING GROWTH FACTOR BETA; TRIACYLGLYCEROL; 1,5-ANHYDRO-1-(5-(4-ETHOXYBENZYL)-2-METHOXY-4-METHYLPHENYL)-1-THIOGLUCITOL; ANTIDIABETIC AGENT; SLC5A2 PROTEIN, MOUSE; SODIUM GLUCOSE COTRANSPORTER 2; SORBITOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DIET RESTRICTION; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; GLYCEMIC CONTROL; IMMUNOHISTOCHEMISTRY; INSULIN BLOOD LEVEL; INSULIN TOLERANCE TEST; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PANCREATIC TISSUE; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DRUG EFFECTS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE; TREATMENT OUTCOME;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPOGLYCEMIC AGENTS; INSULIN-SECRETING CELLS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; OBESITY; SODIUM-GLUCOSE TRANSPORTER 2; SORBITOL; TREATMENT OUTCOME;

EID: 84957441258     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2015.10.109     Document Type: Article

References (24)

1. R. Paul Robertson Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes J. Biol. Chem. 271 2004 42351 42354
2. C.J. Rhodes Type 2 diabetes-a matter of beta-cell life and death? Science 307 2005 380 384
3. P.A. Halban, K.S. Polonsky, D.W. Bowden, and et al. β-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment Diabetes Care 37 2014 1751 1758
4. H. Kaneto, and T.A. Matsuoka Role of pancreatic transcription factors in maintenance of mature β-cell function Int. J. Mol. Sci. 16 2015 6281 6297
5. H. Kaneto, T. Matsuoka, T. Kimura, and et al. Appropriate therapy for type 2 diabetes in view of pancreatic β-cell glucose toxicity: "the earlier, the better" J. Diabetes 2015 (in press)
6. T. Matsuoka, H. Kaneto, T. Miyatsuka, and et al. Regulation of MafA expression in pancreatic β-cells in db/db mice with diabetes Diabetes 59 2010 1709 1720
7. T. Matsuoka, H. Kaneto, S. Kawashima, and et al. Preserving MafA expression in diabetic islet β-cells improves glycemic control in vivo J. Biol. Chem. 290 2015 7647 7657
8. F. Kawasaki, M. Matsuda, Y. Kanda, and et al. Structural and functional analysis of pancreatic islets preserved by pioglitazone in db/db mice Am. J. Physiol. Endocrinol. Metab. 288 2005 E510 E518
9. Y. Kanda, M. Shimoda, S. Hamamoto, and et al. Molecular mechanism by which pioglitazone preserves pancreatic beta-cells in obese diabetic mice: evidence for acute and chronic actions as a PPARgamma agonist Am. J. Physiol. Endocrinol. Metab. 298 2010 E278 E286
10. S. Kawashima, T. Matsuoka, H. Kaneto, and et al. Effect of alogliptin, pioglitazone and glargine on pancreatic β-cells in diabetic db/db mice Biochem. Biophys. Res. Commun. 404 2011 534 540
11. M. Shimoda, Y. Kanda, S. Hamamoto, and et al. The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes Diabetologia 4 2011 1098 1108
12. S. Hamamoto, Y. Kanda, M. Shimoda, and et al. Vildagliptin preserves the mass and function of pancreatic beta cells via the developmental regulation and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes Diabetes Obes. Metab. 15 2013 153 163
13. T. Kimura, H. Kaneto, M. Shimoda, and et al. Protective effects of pioglitazone and/or liraglutide on pancreatic β-cells: comparison of their effects between in an early and advanced stage of diabetes Mol. Cell. Endocrinol. 400 2015 78 89
14. H. Hirukawa, H. Kaneto, M. Shimoda, and et al. Combination of DPP-4 inhibitor and PPARγ agonist exerts protective effects on pancreatic β-cells in diabetic db/db mice through the augmentation of IRS-2 expression Mol. Cell. Endocrinol. 413 2015 49 60
15. Y. Kanai, W.S. Lee, G. You, and et al. The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose J. Clin. Invest. 93 1994 397 404
16. E.C. Chao, and R.R. Henry SGLT2 inhibition-a novel strategy for diabetes treatment Nat. Rev. Drug Discov. 9 2010 551 559
17. C. Clar, J.A. Gill, R. Court, and et al. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes BMJ Open 2 2012
18. D. Vasilakou, T. Karagiannis, E. Athanasiadou, and et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis Ann. Intern Med. 159 2013 262 274
19. J.F. List, V. Woo, E. Morales, and et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes Diabetes Care 32 2009 650 657
20. C.J. Bailey, J.L. Gross, A. Pieters, and et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial Lancet 375 2010 2223 2233
21. J. Rosenstock, N. Aggarwal, D. Polidori, and et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes Diabetes Care 35 2012 1232 1238
22. K. Stenlof, W.T. Cefalu, K.A. Kim, and et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise Diabetes Obes. Metab. 15 2013 372 382
23. H. Rahmoune, P.W. Thompson, and et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes Diabetes 54 2005 3427 3434
24. F.R. Macdonald, J.E. Peel, H.B. Jones, R.M. Mayers, and et al. The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats Diabetes Obes. Metab. 12 2010 1004 1012